Coloplast A/S - Opdateret finanskalender 2025-26 Venligst se vedlagte pdf. Opdatering af datoer i finanskalenderen Coloplast har opdateret datoerne i selskabets finanskalender vedrørende offentliggørelsen af årsregnskabet for 2025/26 samt afholdelsen af den ordinære generalforsamling 2026. De opdaterede datoer er som følger: Årsregnskabsmeddelelse for 2025/26 og Årsrapport 2025/26: ændret fra 5. november 2026 til 3. november 2026Ordinær generalforsamling 2026: ændret fra 3. december 2026 til 1. december 2026 For yderligere information og kalenderinvitationer til kommende beg...
Coloplast A/S - Updated Financial Calendar 2025-26 Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual General Meeting 2026. The updated dates are as follows: Financial Statements for the full year 2025/26 and Annual Report 2025/26: changed from November 5, 2026 to November 3, 2026Annual General Meeting 2026: changed from December 3, 2026 to December 1, 2026 For more information and calendar invitations for upcoming events, please visit: Kind...
FLSmidth: Transactions under share buy-back programme COMPANY ANNOUNCEMENT NO. 10-2026FLSmidth & Co. A/S11 February 2026Copenhagen, Denmark On 25 June 2025, FLSmidth & Co. A/S (“FLSmidth”) initiated a share buy-back programme of up to DKK 1.4 billion (ref. Company Announcement no. 12-2025). Under the share buy-back programme, FLSmidth may repurchase shares up to a maximum amount of DKK 1.4 billion, and no more than 4,600,000 shares, corresponding to approximately 8 percent of the share capital of the company. The share buy-back programme will be executed in accordance with Article 5 of R...
Coloplast A/S - Interim Financial Report, Q1 2025/26 2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT growth1 in constant currencies of 3%. Reported revenue in DKK grew 0%, reflecting 4%-points negative impact from currencies. Return on invested capital2 was 15%. • Organic growth rates by business area: Ostomy Care 4%, Continence Care 7%, Voice & Respiratory Care 8%, Wound & Tissue Repair 5%, and Interventional Urology 8% .• Soft start in Ostomy Care, as expected, driven by negative growth in China and a high...
Coloplast A/S - Regnskabsmeddelelse, Q1 2025/26 2025/26 Delårsrapport, 1. kvartal 2025/261. oktober 2025 - 31. december 2026 Coloplast leverede i 1. kvartal en organisk vækst på 6% og en EBIT vækst1 i faste valutakurser på 3%. Den rapportede omsætning i danske kroner steg 0%, hvilket afspejler en negativ valutaeffekt på 4 procentpoint. Afkast af investeret kapital2 var på 15%. • Organisk vækst pr. område: Stomi 4 %, Kontinens 7 %, Stemme og Respiratorisk Pleje 8 %, Wound & Tissue Repair 5 % og Urologi 8 %.• Svag start i Stomi, som forventet, drevet af negativ vækst i Kina og høj baseli...
FLSmidth announces preliminary and unaudited results for 2025 and full-year 2026 financial guidance COMPANY ANNOUNCEMENT NO. 09-2026 FLSmidth & Co. A/S 5 February 2026 Copenhagen, Denmark Today, FLSmidth & Co. A/S (FLSmidth) announces preliminary and unaudited financial key results for the full year 2025 and introduces its financial guidance for the full year 2026 FLSmidth hereby announces preliminary and unaudited financial figures for the full year 2025. The preliminary financial figures are awaiting finalisation of the company’s independent, customary audit procedures and are theref...
Toni Laaksonen appointed CEO to lead the next phase in FLSmidth’s strategic journey focused on accelerating growth COMPANY ANNOUNCEMENT NO. 08-2026 FLSmidth & Co. A/S 4 February 2026 Copenhagen, Denmark FLSmidth & Co. A/S (FLSmidth) today announces that Toni Laaksonen has been appointed Chief Executive Officer (CEO), effective immediately. Toni joined FLSmidth as Service Business Line President in June 2025. Toni succeeds Mikko Keto, who in November 2025 informed the Board of Directors of his decision to leave the company to pursue an opportunity outside FLSmidth (ref. Company Announcem...
FLSmidth: Transactions under share buy-back programme COMPANY ANNOUNCEMENT NO. 07-2026FLSmidth & Co. A/S4 February 2026Copenhagen, Denmark On 25 June 2025, FLSmidth & Co. A/S (“FLSmidth”) initiated a share buy-back programme of up to DKK 1.4 billion (ref. Company Announcement no. 12-2025). Under the share buy-back programme, FLSmidth may repurchase shares up to a maximum amount of DKK 1.4 billion, and no more than 4,600,000 shares, corresponding to approximately 8 percent of the share capital of the company. The share buy-back programme will be executed in accordance with Article 5 of Re...
FLSmidth & Co. A/S major shareholder announcement COMPANY ANNOUNCEMENT NO. 06-2026 FLSmidth & Co. A/S 3 February 2026 Copenhagen, Denmark FLSmidth & Co. A/S (“FLSmidth” or the “Company”) hereby announces the following notifications received pursuant to sections 38-39 of the Danish Capital Markets Act from Société Générale S.A. regarding its holdings of shares and financial instruments relating to shares in FLSmidth. On 2 February 2026, Société Générale S.A. informed FLSmidth that, as of 28 January 2026, its aggregate holding of shares and financial instruments with a similar economic e...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.